Do you want to read an article? Please log in or register.
Geographic and economic influences on benralizumab prescribing for severe asthma in Japan
Asthma
RECOMMENDED
Related content
ERS 2024
Asthma
BEHAVE: Benralizumab reduces exacerbations and improves asthma control in real-world patients with severe asthma
Asthma
Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry
J Asthma Allergy
Le TT, Price DB, Erhard C, Cook B, Quinton A, Katial R, Christoff GC, Perez-de-Llano L, Altraja A, Bergeron C, Bourdin A, Koh MS, Lehtimäki L, Mahboub B, Papadopoulos NG, Pfeffer P, Rhee CK, Carter V, Martin N, Tran TN, EVEREST Study Working Group
doi: 10.2147/JAA.S468068
Asthma
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH
doi: 10.4168/aair.2025.17.3.384
RECOMMENDED
Asthma
Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Stolz D, Schuoler C, Charbonnier F, Bridevaux PO, Jandus P, Leuppi JD, Pavlov N, Piecyk A, Rothe T
doi: 10.2147/JAA.S495867
RECOMMENDED
Asthma
Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Quarato CMI, Tondo P, Lacedonia D, Soccio P, Pescatore D, Baccellieri ML, Lepore G, Foschino Barbaro MP, Scioscia G
doi: 10.3390/jcm14062075
AsthmaRespiratory Tract Infection
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register
Respir Med
Hansen S, Håkansson KEJ, Soendergaard MB, Bjerrum AS, Schmid JM, Johansson SL, Rasmussen LM, Johnsen CR, von Bülow A, Bonnesen B, Krogh NS, Hilberg O, Dongo L, Vijdea R, Ulrik CS, Porsbjerg C
doi: 10.1016/j.rmed.2025.108203
COMMENTED
Asthma
XALOC-1: Clinical remission over 2-years with benralizumab in severe eosinophilic asthma
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Chest
Pelaia G, Jackson DJ, Nair P, Emmanuel B, Tran TN, Menzies-Gow A, Watt M, Kayaniyil S, Boarino S, Nuevo J, Pardal M, Shavit A, Shih VH, Cohen D, Loureiro C, Padilla-Galo A
doi: 10.1016/j.chest.2025.04.011
RECOMMENDED
Asthma
Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Chiner E, Murcia M, Boira I, Bernabeu MÁ, Esteban V, Martínez-Moragón E
doi: 10.3390/jcm13144247
Asthma
Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study
J Clin Med
Ausín P, Navarrete-Rouco ME, Carazo L, Sanchez-Trincado JL, Luzon E, Nuevo J, Santín M, Sánchez J, Padilla-Galo A
doi: 10.3390/jcm14093011